ABSTRACT
Nowadays, clinical and scientific interest in antibiotics, as polymyxin, has increased due to the large number of reports of multiresistant Gram-negative bacteria, as Pseudomonas aeruginosa. The aim of this study was to investigate a related group of proteins for resistance to polymyxins, encoded by P. aeruginosa genome, through in silico analysis. The mobilized colistin resistance 1 (MCR1) protein from Escherichia coli was used for comparison. Similar sequences to the protein MCR1 in P. aeruginosa were analysed for physicochemical properties. 31 protein isoforms in P. aeruginosa (EptA) were found able to confer resistance to polymyxin showing protein lengths between 551 and 572 amino acids, with molecular mass values between 61.36 - 62. 80 kDa, isoelectric point between 6.10 to 7.17, instability index between 33.76 to 41.87, aliphatic index between 98.67 to 102.63 and the hydropathyindex between - 0.008 to 0.094. These proteins belong to the DUF1705 superfamily with bit-score values between 559.81 and 629.78. A high degree of similarity between EpTAs in P. aeruginosa was observed in relation to other proteins that confer resistance to polymyxins, present in Gram-negative bacteria species of clinical interest. Although, further studies are needed to identify the actual contribution of EptAs in P. aeruginosa species.
ABSTRACT
BACKGROUND: A new strain of human coronavirus (HCoV) spread rapidly around the world. Diabetes and obesity are associated with a worse prognosis in these patients. Congenital Generalized Lipodystrophy (CGL) patients generally have poorly controlled diabetes and require extremely high doses of insulin. There is no documentation in the literature of cases of COVID in CGL patients. Thus, we aimed to evaluate the prevalence of SARS-CoV-2 infection in CGL patients, and the association of their clinical and metabolic characteristics and outcomes. METHODS: This is a cross-sectional study carried out between July and October 2020. Clinical data collected were respiratory or other flu-like symptoms, need of hospitalization in the last three months, CGL comorbidities, and medications in use. Cholesterol, triglycerides, glycohemoglobin A1c levels, anti-SARS-CoV-2 antibodies and nasopharyngeal swab for RT-qPCR were also obtained in all CGL patients. Mann-Whitney U test was used to analyze the characteristics of the participants, verifying the non-adherence of the data to the Gaussian distribution. In investigating the association between categorical variables, we used Pearson's chi-square test and Fisher's exact test. A significance level of 5% was adopted. RESULTS: Twenty-two CGL patients were assessed. Eight subjects (36.4%) had reactive anti-SARS-CoV-2 antibodies. Only one of these, also presented detectable RT-qPCR. Five individuals (62.5%) were women, median age of 13.5 years (1 to 37). Symptoms like fever, malaise, nausea, diarrhea and chest pain were present, and all asymptomatic patients were children. All subjects had inadequate metabolic control, with no difference between groups. Among positive individuals there was no difference between those with AGPAT2 (75%) and BSCL2 gene mutations (25%) (p > 0.05). No patient needed hospitalization or died. CONCLUSIONS: We described a high prevalence of SARS-CoV-2 infection in CGL patients with a good outcome in all of them. These findings suggest that at least young CGL patients infected by SARS-COV-2 are not at higher risk of poor outcome, despite known severe metabolic comorbidities.
ABSTRACT
A utilização de animais para fins científicos configura prática histórica na civilização humana, mas gera polêmica em sociedades preocupadas com proteção dos animais. No Brasil, até 2008, não havia norma ou lei que regulamentasse especificamente a experimentação animal. Este trabalho discute a utilização de animais em experimentos científicos, considerando o delineamento da Lei Arouca, por meio da leitura de artigos científicos que contemplam o histórico da experimentação no contexto mundial e brasileiro, incluindo a regulamentação do uso de animais do filo Chordata, subfilo Vertebrata, em pesquisas no Brasil. A Lei Arouca pode representar avanço na legislação brasileira quanto à utilização de animais para fins científicos, sobretudo pela criação das comissões de ética para uso de animais em instituições de pesquisa e do Conselho Nacional de Controle de Experimentação Animal, que examinam o cumprimento da legislação aplicável em projetos científicos que envolvem a utilização de animais.
The use of animals for scientific purposes is a historical procedure in human civilization, but is controversial for societies concerned with the protection of animals. In Brazil, until 2008, there was no rule or law that specifically regulated animal testing. This paper discusses the use of animals in scientific experiments, considering the Brazilian Arouca Law, through the analysis of scientific articles that consider the history of experimentation in the world and in Brazil, including the regulation of the use of animals of the phylum Chordata, subphylum Vertebrata, in Brazilian research. The Arouca Law may represent an advance in Brazilian law regarding the use of animals for scientific purposes, particularly given the creation of the Ethics Committees for Animal Use in research institutions and the National Council for Animal Experimentation Control, which examine the compliance of scientific projects involving the use of such animals to applicable law.
El uso de animales para fines científicos configura una práctica histórica en la civilización humana, pero genera controversia en las sociedades preocupadas por la protección de éstos. En Brasil, hasta 2008, no había una norma o una ley que regulara la experimentación animal. Este trabajo discute acerca del uso de animales en experimentos científicos, teniendo en cuenta los lineamientos de la Ley Arouca, a partir de la lectura de artículos científicos que abordan la historia de la experimentación animal en el mundo y en el contexto brasilero, incluyendo la regulación del uso de animales del filo Cordados, subfilo Vertebrados, en investigaciones en Brasil. La Ley Arouca puede representar un avance en la legislación brasilera con respecto al uso de estos animales para fines científicos, sobre todo por la creación de las comisiones de ética para el uso de animales (Ceua) en instituciones de investigación y del Consejo Nacional de Control de la Experimentación Animal (Concea), que son los responsables de examinar el cumplimiento de la legislación aplicable a proyectos científicos que involucran la utilización de animales.
Subject(s)
Animals , Male , Female , Bioethics , Technological Development , Animal Rights/legislation & jurisprudence , Animal Experimentation , Biomedical Research , Animals, Laboratory , Animal Technicians , Animal Use Alternatives , Disease Models, AnimalABSTRACT
Methods and techniques employed in gene therapy are reviewed in parallel with pertinent ethical conflicts. Clinical interventions based on gene therapy techniques preferentially use vectors for the transportation of therapeutic genes, however little is known about the potential risks and damages to the patient. Thus, attending carefully to the clinical complications arising as well as to security is essential. Despite the scientific and technological advances, there are still many uncertainties about the side effects of gene therapy. Moreover, there is a need, above all, to understand the principles of bioethics as both science and ethics, in accordance with its socioecological responsibility, in order to prioritize the health and welfare of man and nature, using properly natural resources and technology. Therefore, it is hard to determine objective results and to which extent the insertion of genes can affect the organism, as well as the ethical implication.
Métodos e técnicas empregadas na terapia gênica são revisados em paralelo a conflitos éticos pertinentes. Intervenções clínicas com base em técnicas de terapia gênica são usadas preferencialmente em vetores para o transporte de genes terapêuticos; porém, pouco se sabe sobre os possíveis riscos e danos para o paciente, sendo necessário atender cuidadosamente às complicações clínicas resultantes, bem como à segurança. Apesar dos avanços científicos e tecnológicos relacionados à terapia gênica, ainda há muitas incertezas sobre os efeitos colaterais do uso dessa terapia. Além disso, é necessário, acima de tudo, compreender os princípios da bioética como uma ética da ciência para com a responsabilidade socioecológica, a fim de priorizar a saúde e o bem-estar do homem e da natureza, utilizando adequadamente recursos naturais e tecnologia. Portanto, é difícil afirmar qual é o rendimento real, bem como os resultados do aumento da genética inserida no organismo e as implicações éticas.
Subject(s)
Humans , Bioethical Issues , Gene Transfer Techniques , Genetic Therapy , Attitude of Health Personnel , Patient Safety , Risk Assessment/standards , Social ResponsibilityABSTRACT
Methods and techniques employed in gene therapy are reviewed in parallel with pertinent ethical conflicts. Clinical interventions based on gene therapy techniques preferentially use vectors for the transportation of therapeutic genes, however little is known about the potential risks and damages to the patient. Thus, attending carefully to the clinical complications arising as well as to security is essential. Despite the scientific and technological advances, there are still many uncertainties about the side effects of gene therapy. Moreover, there is a need, above all, to understand the principles of bioethics as both science and ethics, in accordance with its socioecological responsibility, in order to prioritize the health and welfare of man and nature, using properly natural resources and technology. Therefore, it is hard to determine objective results and to which extent the insertion of genes can affect the organism, as well as the ethical implication.
